Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $850 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained the price target of $850.
January 09, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Regeneron Pharmaceuticals and maintained a price target of $850.
The reiteration of a Neutral rating and maintenance of the price target suggests that there is no significant change in the analyst's view on the company's stock. This is likely to have a neutral short term impact on the stock price as it does not alter the investment thesis for current or potential investors.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100